Research programme: uroguanylin-based nanotherapeutics - Pfizer/Synergy Pharmaceuticals

Drug Profile

Research programme: uroguanylin-based nanotherapeutics - Pfizer/Synergy Pharmaceuticals

Latest Information Update: 25 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BIND Therapeutics; Synergy Pharmaceuticals Inc
  • Developer Pfizer; Synergy Pharmaceuticals Inc
  • Class Antineoplastics
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gastrointestinal cancer

Most Recent Events

  • 15 Mar 2016 Preclinical trials in Gastrointestinal cancer in USA (unspecified route) before March 2016
  • 16 Feb 2016 BIND Therapeutics and Synergy Pharmaceuticals agree to co-develop uroguanylin-based nanotherapeutics in USA for Gastrointestinal cancer
  • 16 Feb 2016 Early research in Gastrointestinal cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top